Shanghai Kaibao Pharmaceutical (300039) — Financial Flexibility Index
Shanghai Kaibao Pharmaceutical (300039) has a Financial Flexibility Index of 0.47x as of September 2025. Free cash flow of CN¥194.35 Million (operating CF CN¥190.98 Million minus capex CN¥3.37 Million) represents 0% of total liabilities (CN¥412.55 Million). Check Shanghai Kaibao Pharmaceutical strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Shanghai Kaibao Pharmaceutical Financial Flexibility Index (2006–2024)
Historical Financial Flexibility Index trend for Shanghai Kaibao Pharmaceutical across 19 annual periods. See Shanghai Kaibao Pharmaceutical (300039) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Shanghai Kaibao Pharmaceutical (2006–2024)
Year-by-year free cash flow to debt coverage for Shanghai Kaibao Pharmaceutical. For the full company profile including market capitalisation, see 300039 market cap overview.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.01x | CN¥419.47 Million | CN¥278.95 Million | CN¥415.45 Million | ▲ +34.1% |
| 2023 | 0.75x | CN¥411.74 Million | CN¥382.66 Million | CN¥546.82 Million | ▼ -8.1% |
| 2022 | 0.82x | CN¥408.04 Million | CN¥376.42 Million | CN¥498.24 Million | ▲ +51.0% |
| 2021 | 0.54x | CN¥168.63 Million | CN¥126.08 Million | CN¥310.90 Million | ▼ -38.7% |
| 2020 | 0.89x | CN¥264.59 Million | CN¥250.65 Million | CN¥298.96 Million | ▼ -30.9% |
| 2019 | 1.28x | CN¥349.54 Million | CN¥334.09 Million | CN¥273.01 Million | ▲ +16.4% |
| 2018 | 1.10x | CN¥288.43 Million | CN¥262.36 Million | CN¥262.26 Million | ▲ +17.2% |
| 2017 | 0.94x | CN¥295.00 Million | CN¥245.76 Million | CN¥314.26 Million | ▼ -10.1% |
| 2016 | 1.04x | CN¥341.91 Million | CN¥314.88 Million | CN¥327.61 Million | ▲ +16.4% |
| 2015 | 0.90x | CN¥377.48 Million | CN¥327.08 Million | CN¥421.16 Million | ▼ -40.6% |
| 2014 | 1.51x | CN¥351.12 Million | CN¥282.38 Million | CN¥232.72 Million | ▼ -36.0% |
| 2013 | 2.36x | CN¥388.52 Million | CN¥270.23 Million | CN¥164.72 Million | ▲ +13.6% |
| 2012 | 2.08x | CN¥295.53 Million | CN¥243.32 Million | CN¥142.29 Million | ▲ +46.6% |
| 2011 | 1.42x | CN¥167.16 Million | CN¥98.31 Million | CN¥117.97 Million | ▲ +167.0% |
| 2010 | 0.53x | CN¥70.80 Million | CN¥19.79 Million | CN¥133.39 Million | ▼ -40.8% |
| 2009 | 0.90x | CN¥178.44 Million | CN¥52.74 Million | CN¥199.20 Million | ▲ +207.6% |
| 2008 | 0.29x | CN¥29.98 Million | CN¥18.70 Million | CN¥102.95 Million | ▼ -11.6% |
| 2007 | 0.33x | CN¥27.89 Million | CN¥23.27 Million | CN¥84.64 Million | ▼ -24.7% |
| 2006 | 0.44x | CN¥31.43 Million | CN¥19.70 Million | CN¥71.80 Million | — |